Document Detail

Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression.
MedLine Citation:
PMID:  20850840     Owner:  NLM     Status:  MEDLINE    
PURPOSE: Despite increasing evidence that estrogen signaling has a key role in prostate cancer development and progression, few studies have focused on the estrogen pathway in the transition from hormone sensitive to hormone refractory tumors. We investigated the expression of proteins related to androgen and estrogen metabolism in paired prostate cancer samples collected before androgen deprivation therapy and after hormonal relapse.
MATERIALS AND METHODS: The study included 55 patients treated for prostate cancer only with androgen deprivation therapy and in whom tissue was available before treatment induction and after recurrence. Immunohistochemistry was performed using tissue microarray with antibodies directed against androgen receptor, phosphorylated androgen receptor, estrogen receptor α, estrogen receptor β, 5α-reductase 1 and 2, aromatase, BCAR1 and the proliferation marker Ki67.
RESULTS: Compared to hormone sensitive samples, tissues collected after hormonal relapse were characterized by increased expression of Ki67, androgen receptor, phosphorylated androgen receptor (p <0.001) and BCAR (p = 0.03), and by lower staining for 5α-reductase 2 (p = 0.002), estrogen receptor β (p = 0.016) and aromatase (p <0.001). Shorter time to hormonal relapse was associated with high expression of aromatase and BCAR1 on diagnostic biopsy, together with low staining for estrogen receptor α in stromal cells. Overall survival was significantly shorter when tissues collected after relapse showed a high proliferation index and low estrogen receptor α expression.
CONCLUSIONS: Results revealed dysregulation of proteins involved in androgen pathways, and in estrogen synthesis and signaling during the development of hormone refractory prostate cancer.
Olivier Celhay; Mokrane Yacoub; Jacques Irani; Bertrand Dore; Olivier Cussenot; Gaelle Fromont
Publication Detail:
Type:  Journal Article     Date:  2010-09-17
Journal Detail:
Title:  The Journal of urology     Volume:  184     ISSN:  1527-3792     ISO Abbreviation:  J. Urol.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-11     Completed Date:  2010-11-02     Revised Date:  2011-08-24    
Medline Journal Info:
Nlm Unique ID:  0376374     Medline TA:  J Urol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2172-8     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Service d'Urologie, Centre Hospitalier Universitaire-Université de Poitiers, Poitiers, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Androgens / metabolism*
Antineoplastic Agents, Hormonal / therapeutic use
Disease Progression
Estrogens / metabolism*
Middle Aged
Prostatic Neoplasms / drug therapy,  metabolism*,  pathology*
Protein Biosynthesis*
Treatment Failure
Reg. No./Substance:
0/Androgens; 0/Antineoplastic Agents, Hormonal; 0/Estrogens
Comment In:
J Urol. 2011 Aug;186(2):756   [PMID:  21683411 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prostatic Involution After Intraprostatic Injection of Cobra Toxin.
Next Document:  Pharmacological Inhibition of Cyclin Dependent Kinases Causes p53 Dependent Apoptosis in Renal Cell ...